Evidence map›Paper›PMID 40948890›Full record

ArticleBio-protocol2025

Efficient Gene Knockdown in Adult Zebrafish Retina by Intravitreal Injection.

Eyad Shihabeddin, Abirami Santhanam, Stephan Tetenborg, Alexandra L Aronowitz, John O'Brien

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eyad ShihabeddinDepartment of Ophthalmology & Visual Science, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Abirami SanthanamHuman Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
Stephan TetenborgUniversity of Houston College of Optometry, Houston, TX, USA.
Alexandra L AronowitzDepartment of Ophthalmology & Visual Science, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
John O'BrienUniversity of Houston College of Optometry, Houston, TX, USA.

Funding

Transgenic tools for revealing the contributions of electrical synapses to neural circuitsRF1MH120016 · NIMH · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MILLER, ADAM C, O'BRIEN, JOHN · 2020 to 2020
$3.1M
Rod photoreceptor regeneration in a zebrafish model of Retinitis Pigmentosa.F31EY034793 · NEI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SHIHABEDDIN, EYAD · 2023 to 2025
$82k
NEI NIH HHS F31 EY034793NIMH NIH HHS RF1 MH120016
6 · The paper itself

Abstract

High-throughput sequencing has created a tremendous amount of information about the genes expressed in various cell types and tissues throughout the body. As such, there is a need for a quick and effective method to knock down genes of interest in order to investigate their roles. While there are many approaches for this in mammalian models, there are limited ways to knock down genes of interest in adult zebrafish. Unlike mammals, zebrafish have the natural ability to regenerate their neurons after injury or disease is detected, making them a staple in regenerative studies. Unfortunately, current approaches for gene knockdown in the retina of adult zebrafish are costly and provide a barrier for many scientists. We provide two cost-effective approaches for targeted gene knockdowns in adult zebrafish retinas. We describe this approach through the use of Vivo-morpholinos and lipid-encapsulated siRNAs that target the expression of the proliferating cell nuclear antigen (

Indexed as

Gene knockdownsPhotoreceptorRegenerationRetinal degenerationRetinitis PigmentosasiRNAVivo-morpholino oligonucleotidesZebrafish retina

Identifiers

PMID40948890
PMCPMC12423274

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.